Merck releases phase 2b/3 wet AMD data for tri-specific antibody
Merck & Co. reported phase 2b/3 trial results for Remigromig (MK-3000), a tri-specific antibody for diabetic macular edema (DME). Both doses showed non-inferiority to ranibizumab in improving visual acuity. The drug was generally well-tolerated but had higher rates of certain adverse events. Merck plans to present more data at the AAO meeting. Remigromig was developed by EyeBio, acquired by Merck in 2024.
How this was made
The 30-second read
Why it matters
The BRUNELLO trial data provide the first efficacy read‑out for Merck's tri‑specific antibody, setting expectations for future approvals.
Market read
First disclosure of pivotal ophthalmic trial data; may affect Merck's stock and peers in the eye‑disease space.
What to watch
Long‑term market impact depends on subsequent Phase 3 confirmatory data and potential FDA filing strategy.
Background
Merck acquired EyeBiotech in 2024 and is expanding its ophthalmology pipeline with Remigromig and Tiespectus.
Ticker impact
Merck released topline phase 2b/3 BRUNELLO trial data showing Remigromig was non‑inferior to ranibizumab in diabetic macular edema.
likely limited pressure as investors digest non‑inferiority without clear superiority
First‑time disclosure of pivotal trial results; non‑inferiority limits upside, while higher adverse event rates could temper enthusiasm.
Market effects
May influence other ophthalmic biotech stocks as the data set a benchmark for tri‑specific antibodies.
US biotech sector could see modest movement; limited global effect.
Low; primarily relevant to US‑listed ophthalmic drug developers.
Counterpoint
Investors could view the safety concerns as a red flag and short the stock on potential regulatory scrutiny.
Key entities
- CompanyMerck & Co.
US‑listed pharmaceutical company reporting trial results.
- CompanyEyeBiotech Limited
Acquired by Merck; developer of the Remigromig antibody.
